Lymphodepletion, tumor-infiltrating lymphocytes, and high versus low dose IL-2 followed by pembrolizumab in patients with metastatic melanoma.

Oncoimmunology · 2025 · PMC12360205 · PMID 40815607

Europe PMC DOI

hedged sentence

0.0540

closest p · 1.1× alpha

0.0540

boldest claim

The sentences

a trend toward significancep = 0.054so close (0.05 < p ≤ 0.1)

LAG3 expression declined from week 3 to week 9 ( p = 0.009) and showed a trend toward significance from week 6 to week 9 ( p = 0.054).

also in 3,729 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.